• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

84
7
7
7
2

COUNTRY

7
1

PRICE

13
17
48
129

PUBLISHED

0
13
21
129

PRODUCT TYPE

125
3
1

Breast Cancer

Over a million women worldwide are diagnosed with breast cancer annually. Alongside surgery, radiotherapy and immunotherapy, pharmaceutical products (including hormonal therapy and chemotherapy) are in the frontline against this terrible disease. Market reports in this section enable buyers to read up on the latest breast cancer drug pipelines and R&D strategies, as well as the medical and commercial activities of major players and niche operators such Abraxis Bioscience, Aeterna Zentaris, Agendia BV, Aphton Corp, Array BioPharma, AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly, Genentech, Genta, Novartis AG, Pfizer, Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics, and ViRexx Medical. Also included are cutting edge academic journals and various expert textbooks for medical professionals involved in breast cancer treatment. Show Less Read more

PRODUCT TITLE
Breast Cancer Pipeline Highlights - 2015 Breast Cancer Pipeline Highlights - 2015 - Product Thumbnail Image

Breast Cancer Pipeline Highlights - 2015

The latest report Breast Cancer Pipeline Highlights – 2015, provides most up-to-date information on key pipeline molecules in the global Breast Cancer market. It covers emerging therapies for Breast...

November 2014
FROM
Breast Cancer Drug Pathway Analyzer 2014 Breast Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Breast Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 554 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways...

November 2014
FROM
Breast Cancer Drug Pipeline Update 2014 Breast Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Breast Cancer Drug Pipeline Update 2014

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic...

October 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) -...

September 2014
FROM

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer)...

September 2014
FROM

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer)...

September 2014
FROM

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) -...

September 2014
FROM

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM
PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 - Product Thumbnail Image

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast – Worldwide

Breast cancer is the most common cancer among women in both the developed and developing world. Worldwide Breast Cancer Screening Market was in double digit Billion US$ for 2013. United States is the...

September 2014
FROM
Global Breast Cancer Market Report: 2014 Edition Global Breast Cancer Market Report: 2014 Edition - Product Thumbnail Image

Global Breast Cancer Market Report: 2014 Edition

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location....

August 2014
FROM

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Exceptionally Large and Innovative Pipeline: The breast cancer pipeline is the largest in the pharmaceutical industry with 815 products in active development across all stages. The range of mechanisms...

July 2014
FROM

Global Breast Cancer Market 2014-2018

About Breast Cancer Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically,...

June 2014
FROM

Breast Cancer Treatment Drug Markets in China

China's demand for Breast Cancer Treatment Drug has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's...

June 2014
FROM

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

The leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance...

June 2014
FROM
Analytical Tool - Breast Cancer Analytical Tool - Breast Cancer - Product Thumbnail Image

Analytical Tool - Breast Cancer

"Analytical Tool - Breast Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in breast cancer R&D and business development. It is at the same time...

March 2014
Loading Indicator

Our Clients

Our clients' logos